Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01233128 |
Recruitment Status :
Completed
First Posted : November 3, 2010
Last Update Posted : April 9, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Age-Related Macular Degeneration |
Study Type : | Observational |
Actual Enrollment : | 121 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Association of Vascular Endothelial Growth Factor and LOC387715/HTRA1 Polymorphisms With the Response to Intravitreal Ranibizumab Injections in Polypoidal Choroidal Vasculopathy |
Study Start Date : | October 2010 |
Actual Primary Completion Date : | January 2012 |
Actual Study Completion Date : | January 2012 |

Group/Cohort |
---|
polypoidal choroidal vasculopathy
patients who were treated for polypoidal choroidal vasculopathy with intravitreal injections of 0.5 mg of ranibizumab monthly for 3 months
|
- Best-corrected visual acuity [ Time Frame: up to 12 months ]Best-corrected visual acuity (BCVA) using the Snellen chart was evaluated including BCVA before treatment and BCVA up to 12 months.
- Angiographic characteristics [ Time Frame: up to 12 months ]Fluorescein angiography (FA) and ICGA (HRA; Heidelberg Engineering, Dossenheim, Germany)were evaluated. Greatest linear dimension (GLD) was determined based on both FA and ICGA.
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 60 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- patients older than 60 years of age at onset
- polyp-like terminal aneurysmal dilations with or without branching vascular networks in ICGA and subretinal reddish-orange protrusions corresponding to polyp-like lesions
- patients who had intravitreal injections of 0.5 mg of ranibizumab monthly for 3 months
Exclusion Criteria:
- patients with retinal or choroidal diseases including pathologic myopia, angioid streaks, idiopathic choroidal neovascularization (CNV), presumed ocular histoplasmosis, and other secondary CNV
- patients who refused genotypic analyses

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01233128
Korea, Republic of | |
In Taek Kim | |
Daegu, Kyungsangpookdo, Korea, Republic of, 700-721 |
Principal Investigator: | In Taek Kim, M.D. | Kyungpook National University Hospital |
Publications:
Responsible Party: | Dong Ho Park, clinical professor, Kyungpook National University Hospital |
ClinicalTrials.gov Identifier: | NCT01233128 |
Other Study ID Numbers: |
VEGF & LOC387715/HTRA1 |
First Posted: | November 3, 2010 Key Record Dates |
Last Update Posted: | April 9, 2012 |
Last Verified: | April 2012 |
Macular Degeneration Retinal Degeneration Retinal Diseases Eye Diseases |